delenexCell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and viral infections, announced today the acquisition of Delenex Therapeutics AG, a privately held, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics.

The acquisition will enable Cell Medica to accelerate the development of gene-modified immune cell products with enhanced potency for the treatment of cancer. Delenex’s proprietary PENTRA® technology allows the rapid development of antibody therapeutics within a humanized framework. The Delenex technology and expertise will be integrated with Cell Medica’s product development programme aimed at creating next generation Chimeric Antigen Receptor (CAR)-modified cellular immunotherapies with improved functionality and specificity. Financial details were not disclosed.

Delenex was founded in September 2009 as a spin-off from ESBATech (now a Novartis company). The Delenex scientific team and laboratory facilities based in Schlieren, Switzerland will form a key part of Cell Medica’s international R&D operations and will be re-named Cell Medica Switzerland AG.

Gregg Sando, CEO of Cell Medica, said:

“We are committed to transforming the treatment of cancer through the significant therapeutic potential of cellular immunotherapy. The acquisition of Delenex provides a key enabling technology for the development of an exciting pipeline of next generation CAR-modified cell therapies. We are delighted to welcome the talented team from Delenex and to join the vibrant Swiss biotech community based in Schlieren.”